The Leukemia and Lymphoma Society (LLS) National Research Registry

Blood Cancer Clinical Trial

Official title:

The Leukemia and Lymphoma Society (LLS) National Research Registry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04806295
• Other study ID #: LLSNRR-17-001
• Status: Recruiting
• Start date: July 24, 2017
• Est. completion date: July 23, 2027

Study information

• Verified date: April 2022
• Source: Lymphoma and Leukemia Society
• Contact: Larry Saltzman, MD
• Phone: 844-696-7228
• Email: larry.saltzman[@]lls.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Leukemia and Lymphoma Society (LLS) has built a National Research Registry to evaluate real world experiences and medical outcomes for people with blood cancer, before, during, and after blood cancer treatments.

Description:

The LLS National Research Registry is a real-world experiences and outcomes research registry; a collection of patient information and medical data, over time, about people who have a particular disease or condition, or who receive a particular treatment. The LLS National Research Registry Protocol will: 1. Answer research questions using data collected from people with blood cancers. Such research involves analyses of subject profile information completed by subjects and medical records data. 2. Obtain permission from LLS National Research Registry research subjects to have Ciitizen, a third-party engaged by LLS, act as their proxy to retrieve full medical record data including images at no cost to research subjects. Note: Patient can choose to upload their medical records into their account, directly. 3. Obtain permission from LLS National Research Registry research subjects to share summary data with research partners (like academic researchers, advocacy groups, and pharmaceutical companies) that are advancing treatments for blood cancer. "Summary data" represents the important elements of medical record data, coded for research use, with personal identifiers like name, address, and phone number removed. 4. Obtain permission from LLS National Research Registry research subjects to be contacted from time to time, for them to provide updated medical information.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: July 23, 2027
• Est. primary completion date: July 23, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

People with blood cancer, before, during, and after blood cancer treatments. Exclusion Criteria: People unable or unwilling to sign informed consent.

Related Conditions & MeSH terms

• Blood Cancer
• Hematologic Neoplasms

Intervention

Other:
• any/all treatments for blood cancer
Following people undergoing any/all treatments for blood cancer.

Locations

Country	Name	City	State
United States	Lymphoma and Leukemia Society	Rye Brook	New York

Sponsors (1)

Lead Sponsor	Collaborator
Lymphoma and Leukemia Society

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	LLS will monitor outcomes of people being treated for blood cancer.	. The LLS National Research Registry will collect data on up to 1000 research subjects, over up to 10 years, storing that data, including protected health information (PHI) and images, in secure databases, and share de-identified summary data with research partners (like academic researchers, advocacy groups, and pharmaceutical companies) that are advancing treatments for blood cancer. Participation in The LLS National Research Registry may not give research subjects any immediate benefit. It is hoped the knowledge gained from data collected in The LLS National Research Registry will benefit people with blood cancers in the future using this information for research purposes, directed at blood cancers and associated comorbidities.	10 years